Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Bewertung eines oralen Haarergänzungsmittels zur Verbesserung der Haarstärke und Unterstützung des Wachstums bei Frauen und Männern

10. November 2026 aktualisiert von: Nutraceutical Wellness Inc.

A Single-Center Prospective Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men With Self-Perceived Hair Thinning

A single-center, open-label, prospective study to demonstrate the efficacy of an oral supplement to improve the strength and support the growth of thinning hair in men and women with self-perceived hair thinning.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Female and male subjects will be enrolled in this single-site, open-label, prospective, interventional study evaluating 5 treatment regimens to improve the appearance of thinning hair. All treatment regimens are commercially available nutraceutical hair growth supplements. 50 subjects will be enrolled into each of the 5 supplement groups. Subjects will undergo a baseline, 90 day, and 180 day visit and will have compliance phone calls at Days 45 and 135. Study assessments will include a dermatologist investigator hair assessment, a hair pull test, light microscope hair shaft diameter assessment, and a subject questionnaire.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

250

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • North Carolina
      • High Point, North Carolina, Vereinigte Staaten, 27262
        • Dermatology Consulting Services

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Female or male subjects with concerns and/or signs of hair thinning.
  2. The subjects must meet the age characteristics based on their supplement group assignment.
  3. Subjects are Fitzpatrick Skin Types I to VI.
  4. Subjects must be in good general health.
  5. Subjects must be classified with thinning hair by the study dermatologist.
  6. Willing to maintain the same hair length, hairstyle, and coloring practices for the duration of the study. Subjects who have color-treated hair must have the color treatment performed at the same time interval prior to each visit.
  7. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
  8. Willing and able to adhere to the same dietary lifestyles for the duration of the study
  9. Subjects must express willingness to cooperate with the investigator and comply to study requirements.
  10. Subjects must demonstrate the ability to read and understand all the items in the informed consent document.
  11. Subjects must agree not to use any other hair supplements or start a new vitamin supplement during the study.
  12. Subject has signed an Informed Consent Form in compliance with 21CFR Part 50: "Protection of Human Subjects."
  13. Subject is dependable and able to follow directions and is willing to comply with the schedule of visits.

Exclusion Criteria:

  1. Any previous or current acute or chronic medical or hair condition, which in the investigator's opinion, may interfere with the study results or increase the study participation risks to the subject.
  2. Subjects possessing signs of severe female or male pattern hair loss or alopecia (including androgenetic and traction alopecia) as determined by the study dermatologist.
  3. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  4. Subjects who are not willing to use only the assigned oral study supplement and no new oral supplements during the study.
  5. Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study product.
  6. Subjects, who are pregnant, breast feeding, or planning a pregnancy.
  7. Subjects with clinically significant unstable medical disorders.
  8. Subjects who are unwilling or unable to comply with the requirements of the protocol.
  9. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and/or follow the requirements of the study.
  10. Subjects with any planned surgeries and/or invasive medical procedures during the course of the study.
  11. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
  12. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
  13. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  14. hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
  15. History of burning, flaking, itching, and stinging of the scalp.
  16. Utilization of low-level lasers for hair growth in the last three months.
  17. Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day.
  18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Nutrafol Hair Growth Supplement

5 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.

Hair growth supplement for women ages 18 - 44.

Hair growth supplement for women ages 45 - 70.

Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.

Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Hair growth supplement for men ages 25 - 50.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in hair shaft diameter compared to baseline at Day 180.
Zeitfenster: 180 days

The ability of an oral supplement to improve hair shaft strength as evidenced by change in hair shaft diameter from baseline at Day 180 in new scalp hair growth as viewed by the study dermatologist under a light microscope in men and women with self-perceived thinning hair.

180 days
Change in hair shaft diameter compared to baseline at Day 90.
Zeitfenster: 90 days

The ability of an oral supplement to improve hair shaft strength as evidenced by change in hair shaft diameter from baseline at Day 90 in new scalp hair growth as viewed by the study dermatologist under a light microscope in men and women with self-perceived thinning hair.

90 days

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in broken hairs recovered from the hair pull test compared to baseline at Day 180
Zeitfenster: 180 days

The ability of an oral supplement to improve hair strength as evidenced by a change in the number of broken hairs recovered from the hair pull test at Day 180 compared to baseline in men and women with self-perceived thinning hair.

180 days
Change in broken hairs recovered from the hair pull test compared to baseline at Day 90
Zeitfenster: 90 days

The ability of an oral supplement to improve hair strength as evidenced by a change in the number of broken hairs recovered from the hair pull test at Day 90 compared to baseline in men and women with self-perceived thinning hair.

90 days
Change in hair breakage during the hair pull test compared to baseline at Day 180
Zeitfenster: 180 Days

The ability of an oral supplement to promote longer hair as evidenced by change in hair breakage observed in the hair pull test compared to baseline at Day 180.

180 Days
Change in hair breakage during the hair pull test compared to baseline at Day 90
Zeitfenster: 90 Days

The ability of an oral supplement to promote longer hair as evidenced by change in hair breakage observed in the hair pull test compared to baseline at Day 90.

90 Days
Change in the number of hairs recovered from the hair pull test compared to baseline at Day 180
Zeitfenster: 180 Days

The ability of an oral supplement to improve hair shedding as evidenced by a change in the number of hairs recovered from the hair pull test compared to baseline at Day 180 in men and women with self-perceived thinning hair.

180 Days
Change in the number of hairs recovered from the hair pull test compared to baseline at Day 90
Zeitfenster: 90 Days

The ability of an oral supplement to improve hair shedding as evidenced by a change in the number of hairs recovered from the hair pull test compared to baseline at Day 90 in men and women with self-perceived thinning hair.

90 Days
Subject Self-Perceived Improvement in Hair Quality at Day 180
Zeitfenster: 180 Days

The ability of an oral supplement to improve hair growth and quality in men and women with self-perceived thinning hair as measured by self-assessment questionnaires using a 5-point ordinal scale (0=excellent, 1=good, 2=average, 3=poor, 4=very poor) at Day 180.

180 Days
Subject Self-Perceived Improvement in Hair Quality at Day 90
Zeitfenster: 90 Days

The ability of an oral supplement to improve hair growth and quality in men and women with self-perceived thinning hair as measured by self-assessment questionnaires using a 5-point ordinal scale (0=excellent, 1=good, 2=average, 3=poor, 4=very poor) at Day 90.

90 Days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. Mai 2024

Primärer Abschluss (Tatsächlich)

18. Februar 2025

Studienabschluss (Tatsächlich)

18. Februar 2025

Studienanmeldedaten

Zuerst eingereicht

8. April 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. April 2024

Zuerst gepostet (Tatsächlich)

12. April 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NW-HGN-01

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .